A Study to Compare the Natural History of Ataxia Telangiectasia (AT) in Children to Healthy Comparators (INSPIRE AT)
INSPIRE AT: Longitudinal Study Comparing the Natural History of Ataxia Telangiectasia in Children to Healthy Comparators
The primary objective of this study is to assess the natural history of AT symptoms and disease progression over time in children aged 1 to 10 years old diagnosed with classic AT.
研究概览
地位
条件
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名:Insmed Medical Information
- 电话号码:1-844-446-7633
- 邮箱:medicalinformation@insmed.com
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
Participants who meet all the inclusion criteria and none of the exclusion criteria will be eligible for inclusion in their respective cohort as appropriate.
描述
Inclusion Criteria for the AT Cohort:
- Diagnosis of classic AT based on investigator's assessment of clinical presentation and genotyping.
- If three years to 10 years (<11 years) old, the primary caregiver has self-reported to the site that the participant with AT can walk approximately 33 feet (10 meters) without support from a helper, and without the use of a walking aid.
- Provision of a valid study participant assent form, as applicable, together with a correctly signed and dated primary caregiver informed consent form.
Inclusion Criteria for the Healthy Comparator Cohort:
- Provision of a valid study participant assent form, as applicable, together with a correctly signed and dated primary caregiver consent form.
Exclusion Criteria for the AT Cohort:
- Participation in a clinical trial of a candidate therapeutic for AT, with last administration of a candidate therapeutic within 30 days or five half-lives (whichever is longer) preceding study baseline (start of data collection). For clarity, ongoing clinical trial participation that does not involve a therapeutic drug is acceptable. An exception to this exclusion is that up to approximately 20 participants receiving levacetylleucine (marketed as AQNEURSA®) in investigational trials, expanded access programs, or as a licensed drug are eligible.
- Previous treatment with a chemotherapeutic agent for cancer.
- Diagnosis of a condition other than AT that, in the opinion of the investigator, would compromise AT symptom measurement or current study participation.
Exclusion Criteria for the Healthy Comparator Cohort:
- Diagnosis of any form of AT.
- Previous treatment with a chemotherapeutic agent for cancer.
- Diagnosis of a condition that, in the opinion of the investigator, would compromise the measurement of movement by wearable devices to serve as healthy comparators to AT participants.
Note: Other protocol-defined inclusion/exclusion criteria may apply.
学习计划
研究是如何设计的?
设计细节
- 观测模型:CASE_CONTROL
- 时间观点:PROSPECTIVE
队列和干预
团体/队列 |
|---|
|
AT Cohort
Participants with confirmed AT at screening visit will be enrolled and followed for 24 months. |
|
Healthy Comparator Cohort
Participants without diagnosis of AT at screening visit will be enrolled and followed for 24 months. |
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
AT Cohort: Change From Baseline in AT Neurological Examination Scale Toolkit (A-TNEST) Score
大体时间:Baseline up to Month 24
|
Baseline up to Month 24
|
|
AT Cohort: Change From Baseline in International Cooperative Ataxia Rating Scale (ICARS) Score
大体时间:Baseline up to Month 24
|
Baseline up to Month 24
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change From Baseline in Height
大体时间:Baseline up to Month 24
|
Baseline up to Month 24
|
|
|
Change From Baseline in Weight
大体时间:Baseline up to Month 24
|
Baseline up to Month 24
|
|
|
Percentage of Participants Achieving Pre-defined Developmental Goals as Assessed by Denver Developmental Screening Test (DDST-II)
大体时间:Up to Month 24
|
Up to Month 24
|
|
|
AT Cohort: Change From Baseline in Pediatric Quality of Life Inventory (Peds QL) Score Measured by the Pediatric Quality of Life Inventory
大体时间:Baseline up to Month 24
|
Baseline up to Month 24
|
|
|
Change From Baseline in Motor Activity Assessed by Wearable Device
大体时间:Baseline up to Month 24
|
A wearable accelerometer will capture participant's movements during their everyday activities at home. These data will be processed using specific algorithms to generate measurements that include total sedentary time and time spent in light, moderate and vigorous activity. |
Baseline up to Month 24
|
|
Change From Baseline in Arm Function Assessed by Hevelius Test
大体时间:Baseline up to Month 24
|
Baseline up to Month 24
|
合作者和调查者
调查人员
- 研究主任:Study Director、Insmed Incorporated
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- INS NHS AT001
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.